Residual disease after induction Therapy in Childhood ALL.: 'a highly significant prognostic factor'

被引：0
|
作者：
Cavé, H
ten Bosch, JV
Suciu, S
机构：
来源：
EUROPEAN JOURNAL OF CANCER | 1998年 / 34卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1989 / 1990
页数：2
相关论文
共 50 条
  • [31] Childhood ALL minimal residual disease analysis by proteomics
    Burt, E. C.
    Hussain, F.
    Wright, G.
    Corbo, M.
    Johansson, U.
    Medahunsi, S.
    Cotter, F. E.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2007, 137 : 63 - 63
  • [32] Impact of minimal residual disease prior to allogeneic stem cell transplantation in children with ALL.
    Bader, P
    Hancock, J
    Kreyenberg, H
    Goulden, NG
    Niethammer, D
    Handgretinger, R
    Oakhill, A
    Steward, CG
    Beck, JF
    Klingebiel, T
    [J]. BLOOD, 2000, 96 (11) : 414A - 414A
  • [33] Absolute lymphocyte count at the end of induction therapy is a prognostic factor in childhood acute lymphoblastic leukemia
    Hirase, Satoshi
    Hasegawa, Daiichiro
    Takahashi, Hironobu
    Moriwaki, Kensuke
    Saito, Atsuro
    Kozaki, Aiko
    Ishida, Toshiaki
    Yanai, Tomoko
    Kawasaki, Keiichiro
    Yamamoto, Nobuyuki
    Kubokawa, Ikuko
    Mori, Takeshi
    Hayakawa, Akira
    Nishimura, Noriyuki
    Nishio, Hisahide
    Iijima, Kazumoto
    Kosaka, Yoshiyuki
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 102 (05) : 594 - 601
  • [34] First Application for an approval, which includes minimal Residual Disease as an important Prognostic Factor in ALL
    不详
    [J]. TRANSFUSION MEDICINE AND HEMOTHERAPY, 2019, 46 (01) : 58 - 58
  • [35] Absolute lymphocyte count at the end of induction therapy is a prognostic factor in childhood acute lymphoblastic leukemia
    Satoshi Hirase
    Daiichiro Hasegawa
    Hironobu Takahashi
    Kensuke Moriwaki
    Atsuro Saito
    Aiko Kozaki
    Toshiaki Ishida
    Tomoko Yanai
    Keiichiro Kawasaki
    Nobuyuki Yamamoto
    Ikuko Kubokawa
    Takeshi Mori
    Akira Hayakawa
    Noriyuki Nishimura
    Hisahide Nishio
    Kazumoto Iijima
    Yoshiyuki Kosaka
    [J]. International Journal of Hematology, 2015, 102 : 594 - 601
  • [36] The Presence Of Residual Disease After Induction and/Or Consolidation Therapy Based On Wilms' Tumor 1 (WT1) Expression Is a Strong Prognostic Factor For Relapse and Survival In AML
    Martinez-Laperche, Carolina
    Kwon, Mi
    Carolina Franco-Villegas, Ana
    Chillon, Carmen
    Castro, Nerea
    Dolz, Sandra
    Rodriguez-Medina, Carlos
    Anguita, Eduardo
    Perez, Nuria
    Lopez-Parra, Miriam
    Prieto Conde, M. I.
    Ramos Ortega, F.
    Nicolas Rodriguez, J.
    Hermosin, Lourdes
    Garcia Marco, Jose Antonio
    Gomez Casares, Maite
    Barragan, Eva
    Gonzalez, M.
    Martinez Lopez, Joaquin
    Diez Martin, Jose Luis
    Buno, Ismael
    [J]. BLOOD, 2013, 122 (21)
  • [37] Residual disease after a neoadjuvant therapy: a strong prognostic and potentially predictive biomarker to personalize therapy
    Krop, I.
    [J]. BREAST, 2021, 56 : S13 - S14
  • [38] The post-induction residual disease in childhood ALL correlates to the in-vitro prednisone resistance.
    Schmiegelow, K
    Kaspers, GJL
    Nyvold, C
    Rottier, MMA
    Seyfarth, J
    Pieters, R
    Knabe, N
    Madsen, HO
    Ryder, LP
    [J]. BLOOD, 1998, 92 (10) : 390A - 390A
  • [39] Minimal residual disease in induction therapy is a predictive factor of relapse in standard risk childhood B-precursor acute lymphoblastic leukaemia
    Tutor-Ureta, O
    Díaz, MA
    Algara, P
    Madero, L
    Martínez, P
    [J]. MEDICINA CLINICA, 1999, 113 (04): : 129 - 131
  • [40] Evaluating protocol efficacy by measuring submicroscopic disease reduction during treatment for childhood ALL.
    Roberts, WM
    Johnston, DA
    Ouspenskaia, MV
    Papusha, VZ
    Zipf, TF
    [J]. BLOOD, 1996, 88 (10) : 284 - 284
12345